Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Invested Capital (2016 - 2025)

Cytokinetics (CYTK) has disclosed Invested Capital for 16 consecutive years, with -$618.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital changed N/A to -$618.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$618.4 million, a N/A change, with the full-year FY2025 number at -$618.4 million, changed N/A from a year prior.
  • Invested Capital was -$618.4 million for Q4 2025 at Cytokinetics, down from $390.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $669.7 million in Q2 2024 to a low of -$618.4 million in Q4 2025.
  • A 5-year average of $203.7 million and a median of $243.9 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 550.32% in 2021, then crashed 8202.23% in 2023.
  • Cytokinetics' Invested Capital stood at $243.9 million in 2021, then skyrocketed by 85.86% to $453.2 million in 2022, then tumbled by 61.43% to $174.8 million in 2023, then soared by 213.04% to $547.2 million in 2024, then crashed by 213.02% to -$618.4 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Invested Capital are -$618.4 million (Q4 2025), $390.5 million (Q3 2025), and $192.4 million (Q2 2025).